Paper41576755
Advancements in targeted therapies for acute myeloid leukemia.
Connor MP and 3 others. Curr Opin Pharmacol, 2026. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Advancements in targeted therapies for acute myeloid leukemia. Papers, record 41576755. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41576755
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid, Acute | Major topic |
| Molecular Targeted Therapy | Major topic |
| Antineoplastic Agents | Major topic |
| Humans | |
| Nucleophosmin | |
| fms-Like Tyrosine Kinase 3 | |
| Animals | |
| Isocitrate Dehydrogenase | |
| Histone-Lysine N-Methyltransferase | |
| Mutation | |
| Signal Transduction |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| T32 CA009679 | NCI NIH HHS | United States | T32CA009679 | PubMed |
Source NIH RePORTER
References76
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12951584 | The role of FLT3 in haematopoietic malignancies. | Nat Rev Cancer | 2003 | https://conductscience.org/library/papers/12951584 | PubMed |
| 2 | 37116523 | Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet | 2023 | https://conductscience.org/library/papers/37116523 | PubMed |
| 3 | 36151141 | Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1. | Leukemia | 2022 | https://conductscience.org/library/papers/36151141 | PubMed |
| 4 | 38324741 | Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38324741 | PubMed |
| 5 | 32215183 | Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells. | Oncotarget | 2020 | https://conductscience.org/library/papers/32215183 | PubMed |
| 6 | 30361262 | Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. | Blood | 2019 | https://conductscience.org/library/papers/30361262 | PubMed |
| 7 | 32786187 | Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32786187 | PubMed |
| 8 | 34349242 | Wild-type IDH2 protects nuclear DNA from oxidative damage and is a potential therapeutic target in colorectal cancer. | Oncogene | 2021 | https://conductscience.org/library/papers/34349242 | PubMed |
| 9 | 20538800 | Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. | Blood | 2010 | https://conductscience.org/library/papers/20538800 | PubMed |
| 10 | 26819452 | Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/26819452 | PubMed |
| 11 | 36150050 | Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. | Blood Adv | 2022 | https://conductscience.org/library/papers/36150050 | PubMed |
| 12 | 31841594 | Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. | Blood | 2020 | https://conductscience.org/library/papers/31841594 | PubMed |
| 13 | 17957188 | MLL translocations, histone modifications and leukaemia stem-cell development. | Nat Rev Cancer | 2007 | https://conductscience.org/library/papers/17957188 | PubMed |
| 14 | 35063965 | Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35063965 | PubMed |
| 15 | 35797463 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. | Blood | 2022 | https://conductscience.org/library/papers/35797463 | PubMed |
| 16 | 37871309 | A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML. | Blood Adv | 2024 | https://conductscience.org/library/papers/37871309 | PubMed |
| 17 | 29090343 | Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). | Ann Hematol | 2017 | https://conductscience.org/library/papers/29090343 | PubMed |
| 18 | 35732831 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. | Leukemia | 2022 | https://conductscience.org/library/papers/35732831 | PubMed |
| 19 | 38471061 | Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3. | J Clin Oncol | 2024 | https://conductscience.org/library/papers/38471061 | PubMed |
| 20 | 15464450 | MLL: a histone methyltransferase disrupted in leukemia. | Trends Mol Med | 2004 | https://conductscience.org/library/papers/15464450 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42803869 | ANKRD28 interacts with DOCK180 to activate Rac1-STAT3-Myc signaling and sustain stemness of CD34+ leukemia stem cells in acute myeloid leukemia. | Mol Cell Biochem | 2026 | https://conductscience.org/library/papers/42803869 | PubMed |
| 42452347 | Diagnosis-Driven Targeted Therapy in Acute Myeloid Leukemia: Clinical Integration of Tyrosine Kinase, BCL-2, and CD33-Directed Strategies with Midostaurin, Venetoclax, and Gemtuzumab Ozogamicin. | J Clin Med | 2026 | https://conductscience.org/library/papers/42452347 | PubMed |
| 42188361 | Evolving Management Approaches Toward Personalized Therapy in Acute Myeloid Leukemia: A Narrative Review. | J Pers Med | 2026 | https://conductscience.org/library/papers/42188361 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 | NCBI Gene |
| IDH1 | 3417 | PubTator's text mining | https://conductscience.org/library/genes/3417 | NCBI Gene |
| IDH2 | 3418 | PubTator's text mining | https://conductscience.org/library/genes/3418 | NCBI Gene |
| KMT2A | 4297 | PubTator's text mining | https://conductscience.org/library/genes/4297 | NCBI Gene |
| NPM1 | 4869 | PubTator's text mining | https://conductscience.org/library/genes/4869 | NCBI Gene |
| RET | 5979 | PubTator's text mining | https://conductscience.org/library/genes/5979 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41576755
GET https://conductscience.org/api/papers/v1/41576755/references?page=2